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S U M M A R Y
Objective: To determine the molecular epidemiology and presence of virulence genes in community-
acquired (CA) and hospital-acquired (HA) methicillin-resistant Staphylococcus aureus (MRSA) isolates
and their relationship to clinical outcomes.
Methods: An observational and prospective study of infections caused by MRSA was conducted between
June 2006 and December 2007 across seven hospitals in three Colombian cities. MRSA isolates were
analyzed for SCCmec. Also, pulsed-ﬁeld gel electrophoresis and multilocus sequence typing were
performed and 25 virulence genes were identiﬁed.
Results: Two hundred and seventy isolates were collected from 262 adult hospital patients with MRSA
infections. Overall, 68% of the isolates were classiﬁed as HA-MRSA and 32% as CA-MRSA. We identiﬁed
differences in the patterns of virulence genes: 85% of HA-MRSA isolates possessed the enterotoxin gene
cluster (egc), whereas 92% of CA-MRSA isolates possessed the lukF-PV/lukS-PV genes. Multivariate
analysis showed an increased risk of mortality for seg (p = 0.001, odds ratio 4.73) and a protective effect
for eta (p = 0.018, odds ratio 0.33).
Conclusions: Our study conﬁrms that three clones of MRSA predominantly circulate in Colombia: a
Chilean clone, a pediatric clone that causes HA-MRSA infections, and a USA300-related clone (SCCmec
IVc) in CA-MRSA infections, which differ in the content of clinically important virulence genes. This study
conﬁrms that PVL is not a determinant of severity or mortality in CA-MRSA infections.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Methicillin-resistant Staphylococcus aureus (MRSA) is a patho-
gen mainly associated with hospitals (HA-MRSA). In South
America, the two predominant HA-MRSA clones are the Brazilian
clone (sequence type ST239), which bears the staphylococcal* Corresponding author. Tel.: +61 43 5431889; fax: +61 2 98785922.
E-mail address: natashavanegas@yahoo.es (N.V. Go´mez).
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http://dx.doi.org/10.1016/j.ijid.2013.02.029cassette chromosome (SCC) mec III (MRSA-ST239-III),1 and the
Chilean/Cordobes clone (MRSA-ST5-I).2 However, in recent years,
MRSA has become an important cause of community-acquired
infections (CA-MRSA). USA300 is one of the main clones
representing CA-MRSA and has disseminated throughout Latin
America as well as some European countries.1,3 In Uruguay and
Brazil, CA-MRSA isolates have been reported that display distinct
genetic characteristics (MRSA-ST30-IVc).4 The dissemination of
CA-MRSA isolates in hospital environments was reported in
Colombia in 2009. In the Andean countries (Colombia, Venezuela,ses. Published by Elsevier Ltd. All rights reserved.
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acteristics to the USA300 clone, including MRSA-ST8-IVc-E, Panton–
Valentine leukocidin (PVL) positivity, and multi-susceptibility.5,6
Staphylococcus aureus is a pathogen with the ability to produce a
series of virulence factors that contribute to the severity of
infections. These factors include microbial surface components
that recognize adhesive matrix molecules (MSCRAMM), cytolytic
toxins, exoenzymes, exotoxins, hemolysins, leukocidins (such as
PVL), and superantigens. The group of superantigens includes
staphylococcal enterotoxins (SE), toxic shock syndrome toxin
(TSST), and exfoliative toxins. These exoenzymes and exotoxins
demonstrate proteolytic activity and toxic or lytic effects in the
cells, facilitating local invasion and dissemination.7
The increase in the prevalence of infections caused by CA-MRSA
in hospitals and the difﬁculty in differentiating them using the
clinical and epidemiological criteria of HA-MRSA, has shown that it
is necessary to use genetic markers for their correct classiﬁcation.8
The objective of this study was to determine the presence of
virulence genes in CA-MRSA and HA-MRSA isolates and to
establish their possible relationship to clinical outcomes. This
knowledge will contribute to our understanding of how the MRSA
epidemic has evolved.
2. Materials and methods
2.1. Study population
A prospective cohort study was carried out between June 2006
and December 2007. The study was based on an active surveillance
of all MRSA infections in patients older than 18 years who attended
seven third-level hospitals in Colombia. MRSA isolates included in
the present study were collected prospectively and the ﬁrst strain
isolated from each patient was analyzed. The quality of the sample
was monitored by the study coordinator at each hospital, in
accordance with the local protocol. Clinical specimens included
blood, secretions from complicated skin and soft tissue infections
and postsurgical wound infections, bronchoalveolar lavage, and
endotracheal aspirate culture and sterile liquid samples. Isolates
recovered from catheters and sputum and those recovered from
skin without clinical justiﬁcation were excluded. All MRSA isolates
identiﬁed at each hospital were sent to a reference laboratory
where identiﬁcation was conﬁrmed by phenotypic and genotypic
methods. Clinical data related to the type of infection and outcome
(death, improvement, and relapse), as well as other data, were
collected and stored in a database designed for this purpose for up
to a period of 30 days after the diagnosis of infection by MRSA.
2.2. Bacterial isolates and reference strains
Two hundred and seventy isolates were collected from 262
adult hospital patients diagnosed with an infection caused by
MRSA. The reference strains used were Mu50, JCSC4744, JCSC2172,
81/108, JCSC4469 (donated by Teruyo Ito), NPS123, USA500,
TC146, FRI1151 (kindly provided by Dr Jerome Etienne), and
USA300-0114.
2.3. SCCmec typing and virulence factor gene detection
Conﬁrmation of the species and methicillin resistance in the
isolates was achieved through the ampliﬁcation of the nuc and
mecA genes, respectively.9 The types and subtypes of SCCmec
were also evaluated.10 The presence of the genes that code for
PVL (lukF-PV and lukS-PV), 15 staphylococcal enterotoxins (sea–
see, seg–seo, and seq), two exfoliative toxins (eta and etb), gamma
hemolysin (hlg), and the toxic shock syndrome toxin (tst) was
determined using previously reported methodologies, with somemodiﬁcations.11,12 Additionally, isolates were examined for the
presence of clfA, clfB, ﬁb, fnbA, and fnbB genes for adhesive proteins
and the ica operon, which is related to bioﬁlm formation.13 The
localization of seq and sek genes into pathogenicity island 5 was
conﬁrmed by PCR.
2.4. Pulsed-ﬁeld gel electrophoresis (PFGE) and multilocus sequence
typing (MLST)
The genetic relationship of the isolates was determined by
PFGE.2 The electrophoretic patterns were analyzed with the
Gelcompare II program (Bio-Rad Laboratories, Hercules, CA,
USA) using a Dice similarity coefﬁcient. The isolates with >75%
similarity were clustered in patterns. The isolates were classiﬁed
according to the criteria described by Tenover et al.14 MLST was
carried out in accordance with the protocol described by Enright
et al.15
2.5. Antibiotic susceptibility proﬁle
The minimal inhibitory concentration (MIC) was determined
for 11 antibiotics (oxacillin, gentamicin, rifampin, erythromycin,
ciproﬂoxacin, vancomycin, linezolid, tetracycline, clindamycin,
trimethoprim, and sulfamethoxazole) by the agar dilution
method.16 The inducible clindamycin resistance was determined
by D-test.16
2.6. Statistical analysis
Relative risk or virulence factor protection was evaluated using
the diagnosis of the patient’s infection, and clinical outcome
(mortality or improvement) was determined by applying the
asymptotic or exact Pearson’s Chi-square test (expected values <5)
to two tails or one tail when signiﬁcant clinical differences were
expected. The force of the association was evaluated using the odds
ratio (OR) with reliability intervals of 95%. The multicollinearity
between the virulence factors and the coefﬁcient of force was
previously evaluated by the contingency coefﬁcient, Phi, and
Cramer’s V. A model for the explanation and control of confounding
variables was constructed for infections where the results were
either improvement or mortality, using a multivariate analysis
with the model of unconditional logistic regression. The statistical
tests were evaluated as having a level of signiﬁcance at 5%
(p < 0.05).
3. Results
3.1. Genetic relationship by PFGE
Nine electrophoretic patterns were obtained from the 270
MRSA isolates. Pattern F, present in 162 isolates (60.0%), had a
genetic similarity with the Chilean clone of >77.8%. Pattern U,
related to the USA300-0114 clone, was found in 86 (31.8%) isolates
of which only one was genetically indistinguishable, while 85
isolates presented a genetic similarity with the clone of >79.9%.
Pattern D, present in four isolates (1.5%), showed a similarity with
the pediatric clone of 79% (Figure 1). Eighteen isolates presented
pulsotypes that were not related to these three patterns (patterns
G, H, K, O, and P).
3.2. Analysis by MLST
Twelve isolates were selected for typing by MLST according to
their PFGE pattern. Two new alleles were obtained for the arcC
gene with variations in only one nucleotide: ST1110 (938-4-1-4-
12-1-10) in two isolates related to the Chilean clone and ST1111
Figure 1. Patterns of pulsotypes obtained by PFGE, SCCmec, and virulence factor proﬁles in representative MRSA isolates. PFGE type F (Chilean clone), D (pediatric clone), and
G (non-related clone), which correspond to HA-MRSA, and type U (clone USA300), which corresponds to CA-MRSA infections, staphylococcal cassette chromosome mec
(SCCmec), multilocus sequence typing (MLST), Panton–Valentine leukocidin (PVL), exfoliative toxin A (eta), exfoliative toxin B (etb), the ica operon (ica), clumping factors A
and B (clfA/B), ﬁbrinogen binding protein (ﬁb), ﬁbronectin binding protein A and B (fnbA/B), enterotoxin I (sei), enterotoxin G (seg), enterotoxins M, N, and O (sem, sen, and seo),
enterotoxin K (sek), enterotoxin Q (seq), and enterotoxins D and J (sed and sej).
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These two ST are a single locus variant (SLV) of ST5. Three isolates
were related to the Chilean clone, and one isolate was related to the
pediatric clone with ST5. Five representative isolates of the
predominant patterns U1, U2, and U3 were variants of ST8.
3.3. SCCmec typing, detection of the arginine catabolic mobile
element (ACME), and susceptibility proﬁles
All isolates with patterns F and D had SCCmec types I and IV,
respectively. In pattern G, nine isolates were type II and one
isolate was type I. In pattern H, the isolates were type III; in
patterns O and P, the isolates were type I; and in patterns R and K,
the isolates were type II. Among the 86 CA-MRSA isolates,
SCCmec IVc was found in 82 isolates (95%), followed by IVa and
IVb in three (3%) and one (2%) of the isolates, respectively
(Figure 1). The presence of ACME was detected in only one CA-
MRSA isolate (COL207), which was genetically indistinguishable
from the USA300-0114. In accordance with the PFGE patterns
and SCCmec type, 86 (31.9%) isolates were classiﬁed as CA-MRSA
and 184 (68.1%) as HA-MRSA.
In HA-MRSA, the presence of SCCmec I, II, and III was related to
the resistance proﬁles reported, of which 31.5%, 60.9%, and 7.6%Table 1
Detection of the virulence factor genes of MRSA in accordance with the clinical diagno
Gene Number and percentage of the Staphylococcus aureus isolates (N =
Bacteremia
(n = 85; 34.0%)
Infection of the surgical site
(n = 74; 29.6%)
Infection
(n = 60; 2
ica operon 85 (100) 73 (98.6) 59 (98.3)
clf A/B 85 (100) 74 (100) 56 (93.3)
ﬁb 84 (98.8) 72 (97.3) 56 (93.3)
fnbA/B 15 (17.6) 7 (9.5) 32 (53.3)
eta 72 (84.7) 67 (90.5) 50 (83.3)
sem, sen, seo 75 (88.2) 64 (86.5) 16 (26.7)
sei 63 (74.1) 57 (77.0) 13 (21.7)
seg 71 (83.5) 63 (85.1) 15 (25.0)
sek 8 (9.4) 7 (9.5) 35 (58.3)
seq 9 (10.6) 7 (9.5) 36 (60.0)
PVL 8 (9.4) 9 (12.2) 39 (65.0)presented co-resistance to four, ﬁve, and six antibiotics, respec-
tively. Among CA-MRSA isolates, 37.2% did not exhibit resistance to
non-b-lactam antibiotics and 30.2% of the isolates were resistant
to tetracycline. Co-resistance to three antibiotics was found in
16.2% (oxacillin–ciproﬂoxacin–tetracycline and oxacillin–erythro-
mycin–clindamycin), co-resistance to four antibiotics in 3.4%, and
co-resistance to ﬁve antibiotics in 4.6% of the isolates.
3.4. Virulence factors
Among isolates classiﬁed as HA-MRSA, the sem, sen, and seo
genes were detected in 184 isolates (100%); the seg gene was found
in 173 isolates (94%) and 154 isolates (85%) possessed the sei gene.
These ﬁve genes make up the enterotoxin gene cluster (egc). The
exfoliative toxin A was found in 52 (60.5%) CA-MRSA isolates and
171 (92.9%) HA-MRSA isolates. The exfoliative toxin B was found in
four (2.1%) isolates, and the sed and sej genes were found in 2 (1.0%)
isolates from the pattern F (HA-MRSA). The sek, seq, and lukF-PV/
lukS-PV genes were detected only in the CA-MRSA isolates
(Figure 1). The ﬁbronectin binding proteins A and B (fnbA and
fnbB) were mainly detected in CA-MRSA isolates (Figure 1). The
clfA, clfB, and ﬁb genes were detected in all isolates. The hlg, tst, sea,
seb, sec, see, seh, and sel genes were not found.sis of the associated infection
 250), n (%) p-Value
 of skin and soft tissue
4.0%)
Pneumonia
(n = 16; 6.4%)
Other diagnosis
(n = 15; 6.0%)
 16 (100) 15 (100) 0.634
 16 (100) 15 (100) 0.006
 15 (93.8) 13 (86.7) 0.206
 0 2 (13.3) <0.001
 15 (93.8) 14 (93.3) 0.537
 16 (100) 13 (86.7) <0.001
 14 (87.5) 10 (66.7) <0.001
 16 (100) 12 (80) <0.001
 0 2 (13.3) <0.001
 0 2 (13.3) <0.001
 0 2 (13.3) <0.001
Table 3
Relationship between clinical improvement and the presence of virulence factors of
MRSA (N = 250)
Virulence factor Presence Improvement, n (%) p-Value RR 95% CI
sem, sen, seo Pos 127 (69.0) 0.017 0.83 0.72–0.96
Neg 55 (83.3)
sei Pos 108 (68.8) 0.043 0.87 0.75–1.00
Neg 74 (79.6)
seg Pos 120 (67.8) 0.004 0.80 0.69–0.92
Neg 62 (84.9)
sek Pos 44 (84.6) 0.021 1.21 1.05–1.41
Neg 138 (69.7)
seq Pos 45 (83.3) 0.033 1.19 1.03–1.39
Neg 137 (69.9)
eta Pos 164 (89.4) 0.048 1.31 0.95–1.80
Neg 18 (68.4)
PVL Pos 48 (82.8) 0.035 1.19 1.02–1.38
Neg 134 (69.8)
MRSA, methicillin-resistant Staphylococcus aureus; RR, relative risk; CI, conﬁdence
interval.
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During the study, the clinical data of 247 patients with 250
MRSA isolates were analyzed. One hundred and eighty-four
isolates (73.6%) were classiﬁed as HA-MRSA and 66 isolates
(26.4%) were classiﬁed as CA-MRSA. Our study showed a
statistically signiﬁcant association between mortality and HA-
MRSA infection compared with CA-MRSA infections (26.1% vs.
10.6%; relative risk (RR) 2.46, 95% conﬁdence interval (CI) 1.17–
5.16, p < 0.009). Similarly, an increased mortality was found in
patients with bacteremia (45.9%) and pneumonia (43.8%) com-
pared with surgical site infection (10.8%) and other diagnoses
(6.7%) (p < 0.001). Table 1 shows the association between clinical
diagnosis and the presence of different virulence genes. The
enterotoxin gene cluster (egc) was detected in a higher proportion
in patients with bacteremia and pneumonia caused by HA-MRSA
(p < 0.001). sek, seq, and lukF-PV/lukS-PV genes were signiﬁcantly
associated with soft tissue infection, and proved to be signiﬁcant
markers of CA-MRSA isolates (p < 0.001). The lukF-PV/lukS-PV
genes were not found in MRSA isolates causing pneumonia.
Tables 2 and 3 show the relationships between virulence factors
and clinical outcomes. In patients with HA-MRSA infections, the
presence of sem, sen, seo, sei, and seg genes and the diagnosis of
bacteremia or pneumonia signiﬁcantly increased the risk of
mortality (RR 4.66, 95% CI 2.73–7.95, p < 0.001 for sem, sen, seo
genes, RR 3.93, 95% CI 2.44–6.35, p < 0.001 for the sei gene, and RR
5.00, 95% CI 2.93–8.52, p < 0.001 for the seg gene). Paradoxically, in
the bivariate analysis, the sek and seq genes showed a protective
effect with regard to mortality. This effect was also related to
clinical improvement for the same toxins combined with the eta
virulence factor. However, in the multivariate analysis and
measurement of the multicollinearity between the detection of
different virulence factors, increases in the risk of mortality for seg
(p = 0.001, OR 4.73, 95% CI 1.88–11.87) and in the protective effect
for eta (p = 0.018, OR 0.33, 95% CI 0.13–0.83) were observed. The
multivariate model of clinical improvement showed the same
results, with seg (p = 0.002, OR 0.29, 95% CI 0.13–0.63) and eta
(p = 0.022, OR 2.74, 95% CI 1.15–6.52).
4. Discussion
Staphylococcus aureus possesses an extensive repertoire of
virulence factors that contribute to its survival and the develop-
ment of pathologies of variable complexity. It is not easy to
establish a clear proﬁle of the virulence factors that explain the
differences in the pathological processes that cause CA-MRSA and
HA-MRSA. This is due to the variations in the genetic content of the
MRSA lineage that contribute to its diversiﬁcation and evolution.8Table 2
Relationship between mortality associated with infections caused by MRSA and the
presence of the virulence factor genes (N = 250)
Virulence factor Presence Mortality, n % p-Value RR 95% CI
sem, sen, seo Pos 48 (26.1) 0.006 2.46 1.17–5.16
Neg 7 (10.6)
sei Pos 41 (26.1) 0.028 1.74 1.00–3.01
Neg 14 (15.1)
seg Pos 48 (27.1) 0.001 2.83 1.34–5.96
Neg 7 (9.6)
sek Pos 5 (9.6) 0.009 0.38 0.16–0.91
Neg 50 (25.3)
seq Pos 6 (11.1) 0.019 0.44 0.20–0.98
Neg 49 (25.0)
PVL Pos 6 (10.3) 0.009 0.41 0.18–0.90
Neg 49 (25.5)
MRSA, methicillin-resistant Staphylococcus aureus; RR, relative risk; CI, conﬁdence
interval.The present study, through the genetic detection of the virulence
factors, aimed to contribute to the understanding of the genetic
basis underlying the possible association of MRSA with a particular
epidemiological behavior.
In Latin America, the presence of some virulence factors in CA-
MRSA isolates has been reported. However, the epidemiological
and genetic correlation between the proﬁle of the virulence genes
present in the different CA-MRSA and HA-MRSA clones and their
clinical results has not yet been determined.6,17 This study details
the coexistence of three MRSA clones that are predominant in
Colombia: the Chilean clone and the pediatric clone that cause HA-
MRSA infections, and a USA300-related clone (SCCmec IVc) that
causes CA-MRSA infections. This study also highlights the
discovery of two new allelic combinations, ST1110 and ST1111,
both SLV of ST5, in the Chilean and Pediatric clones, respectively.
This ﬁnding demonstrates the existence of constant genetic change
in not just CA-MRSA but also in HA-MRSA. These bacteria undergo
genetic variations that can give rise to isolates with greater
capacities for environmental adaption.
In terms of virulence factors, differential content was reported
between CA-MRSA and HA-MRSA isolates. Eighty-ﬁve percent of
the HA-MRSA isolates possessed the enterotoxin gene cluster (egc),
generally contained in the genomic island b type I. In contrast, the
lukF-PV/lukS-PV, sek, and seq genes were found in the majority of
CA-MRSA infections (92%, 80%, and 82% of CA-MRSA isolates,
respectively). The last ones are transported by the pathogenicity
island 5 (SalP5).
This study conﬁrms that HA-MRSA clones predominantly carry
the egc cluster, as reported in Europe, the USA, and Japan.18 The egc
cluster is predominant in the HA-MRSA isolates related to the
Chilean clone. From a clinical point of view, 40% of isolates came
from patients with bacteremia and 35% from patients with surgical
wound infections. It is therefore probable that one or more of the
enterotoxins codiﬁed from the egc is not found in severe infections,
but this conclusion seems contradictory if we consider that the
enterotoxins, due to their nature as superantigens, induce an
increase in capillary permeability, hypertension, and other
symptoms related to toxic shock syndrome.7 Ferry et al.19
described a greater prevalence of the egc-positive isolates
recovered from surface infections compared to invasive infections.
The prevalence of the egc cluster signiﬁcantly declined as the
severity of the infection increased. van Belkum et al.20 did not ﬁnd
any evidence of an association of the egc cluster with mortality in
patients with MRSA-related bacteremia. The bivariate analysis
does not demonstrate a global association with mortality. After
analyzing all of the models and measuring their multicollinearity, a
signiﬁcant increase in the risk of mortality was evident among
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(p = 0.001).
Regarding the signiﬁcant association with mortality, Dau-
walder et al. showed in septic shock models that seg does not
induce a proinﬂammatory response related to increasing the
severity of the infection. The prevalence of egc-harboring strains
was higher among strains causing suppurative infections than in
those causing invasive diseases.21 Ferry et al. also observed a
negative relationship between the egc cluster and clinical
severity.19 A similar analysis can infer that the presence of the
seg gene is related to a worsening clinical result. Bae et al. described
similar deterioration in clinical results through the presence of
some seg genes, but they also found a paradoxically higher rate of
clinical healing through the presence of some adhesive genes.22
The fnbA and fnbB genes were mainly detected in CA-MRSA
isolates compared to HA-MRSA isolates (77% vs. 3%). These genes
have been related to the increase in the adhesive and formation of
bioﬁlm capacity of S. aureus.23 From the physiopathological point
of view, this is related to the clinical diagnosis, as it was found in
64% of patients with skin and soft tissue infections (SSTI) and in
20% of patients with bacteremia. The adhesion of S. aureus to the
endothelium depends on the fnbA and fnbB genes. These also
signiﬁcantly improve the movement of bacteria to the blood-
stream, the colonization of organs such as the kidneys,24 and the
development of sepsis.25 In this study, 92% of the CA-MRSA isolates
carried the lukF-PV/lukS-PV genes, which is a higher percentage
than that reported in the USA26 and some European countries.27
The isolates related to the USA300 clone were characterized by
the presence of the PVL gene, which was found in 85% of patients
with SSTIs, a rate similar to that reported in the USA.28 There was
no statistically signiﬁcant association between the presence of PVL
and mortality, as it was only detected in 10% of patients with CA-
MRSA infections who died compared to 82% of patients who
improved (p = 0.009), similar to the ﬁndings reported by Wang
et al.29 In a multicenter study by Bae et al. conducted with 522
patients with complicated SSTIs in the USA, 85% of isolates were
associated with the lukF-PV/lukS-PV genes and these patients
exhibited a signiﬁcantly higher probability of recovery compared
to those infected by PVL-negative MRSA (91.6% vs. 80.7%,
p = 0.015).22 These results are consistent with previous studies
of patients with bacteremia and SSTIs and suggest that the
presence of PVL is related to favorable and improved clinical
results.30 Additionally, this study did not ﬁnd a relationship
between the presence of PVL and pneumonia. This ﬁnding is in
contrast to the relationship previously described in Spanish
patients with pulmonary diseases.31
An important ﬁnding in this study was the high detection rate of
the eta gene in both CA-MRSA and HA-MRSA isolates, as well as its
absence in all cases that were related to the clinical presence of
bullous impetigo (data not shown). Surprisingly, the eta gene was
related to favorable results compared with those described in other
publications, in which its detection was minimal or absent.32 This
ﬁnding is consistent with previously reported studies of these
genes, but there is still a lack of correlation with clinical results.21
Furthermore, it has to be taken into account that the clinical
outcome of an infection is not dependent only on the virulence
factors of the bacteria; in fact the outcome is due to multiple
factors, such as immunological factors, co-morbidity of the host,
anatomic site of the infection, proper antibiotic treatment, and
prompt diagnosis and treatment, among others. Such clinical
variables were not included in the multivariate analysis, this being
a limiting factor of this study in the interpretation of our ﬁndings
related to mortality and clinical recovery.
In conclusion, isolates of CA-MRSA and HA-MRSA in our study
expressed differential patterns of virulence genes, predominantly
the enterotoxin gene cluster (egc) in HA-MRSA isolates and sek, seq,and lukF-PV/lukS-PV genes detected only in the CA-MRSA. In
patients with HA-MRSA infections, the presence of sem, sen, and seo
genes and the diagnosis of bacteremia or pneumonia signiﬁcantly
increased the risk of mortality (RR 4.66, 95% CI 2.73–7.95,
p < 0.001). PVL was not found to be a determinant of severity or
mortality in CA-MRSA infections. It is necessary to conduct
additional studies to clarify the interactive processes of the
virulence, pathogenicity, and clinical results.
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